No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes

To study the acute effect of nateglinide, an insulinotropic agent, on the postprandial triglyceride and lipoprotein responses in subjects at risk for type 2 diabetes.

[1]  L. Lönn,et al.  Early alterations in the postprandial VLDL1 apoB‐100 and apoB‐48 metabolism in men with strong heredity for type 2 diabetes , 2004, Journal of internal medicine.

[2]  C. Sala,et al.  Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. , 2003, Experimental and clinical endocrinology & diabetes.

[3]  T. Funahashi,et al.  Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[4]  T. Funahashi,et al.  Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. , 2003, Diabetes.

[5]  J. Gill,et al.  Exercise and postprandial lipid metabolism: an update on potential mechanisms and interactions with high-carbohydrate diets (review). , 2003, The Journal of nutritional biochemistry.

[6]  M. Frenneaux,et al.  Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus , 2003, European journal of clinical investigation.

[7]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[8]  L. Bouter,et al.  Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study , 2002, European journal of clinical investigation.

[9]  L. Groop,et al.  Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. , 2002, Diabetes care.

[10]  M. Taskinen,et al.  Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes , 2002, Diabetes/metabolism research and reviews.

[11]  R. Kawamori,et al.  Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. , 2002, Biological & pharmaceutical bulletin.

[12]  B. Howard,et al.  Dyslipidemia of the metabolic syndrome , 2002, Current cardiology reports.

[13]  P. Maheux,et al.  Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue‐specific manner , 2002, European journal of clinical investigation.

[14]  D. Owens,et al.  Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  C. Williams.  Beneficial nutritional properties of olive oil: implications for postprandial lipoproteins and factor VII. , 2001, NMCD. Nutrition Metabolism and Cardiovascular Diseases.

[16]  H. Esterbauer,et al.  Postprandial lipemia and coronary risk , 2000, Current atherosclerosis reports.

[17]  S. Subramanian,et al.  Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  R. Sato,et al.  Sterol Regulatory Element-binding Protein Negatively Regulates Microsomal Triglyceride Transfer Protein Gene Transcription* , 1999, The Journal of Biological Chemistry.

[19]  M. Taskinen,et al.  Postprandial Hypertriglyceridemia and Insulin Resistance in Normoglycemic First-Degree Relatives of Patients with Type 2 Diabetes , 1999, Annals of Internal Medicine.

[20]  Taskinen,et al.  Comparison of three fatty meals in healthy normolipidaemic men: high post‐prandial retinyl ester response to soybean oil , 1998, European journal of clinical investigation.

[21]  M. Taskinen,et al.  Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. , 1998, Diabetes.

[22]  M. Taskinen,et al.  Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM , 1997, Diabetologia.

[23]  M. Akiyoshi,et al.  Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)‐N‐(trans‐4‐isopropylcyclohexane‐carbonyl)‐d‐phenylalanine (A‐4166) , 1997, British journal of pharmacology.

[24]  L. Groop,et al.  Metabolic Consequences of a Family History of NIDDM (The Botnia Study): Evidence for Sex-Specific Parental Effects , 1996, Diabetes.

[25]  J. Björkegren,et al.  Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[26]  A. Hamsten,et al.  Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. , 1994, Journal of lipid research.

[27]  L. Niskanen,et al.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects , 1993, Diabetologia.

[28]  S Senn,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.

[29]  L. Groop,et al.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.

[30]  H. Sköldborn,et al.  A New Whole Body Monitoring Laboratory , 1972, Acta radiologica. Supplementum.